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Abstract Here we show that in extrahepatic methionine
adenosyltransferase replacement of a single amino acid (glycine
120) by cysteine is sufficient to create a functional nitric oxide
binding site without affecting the kinetic properties of the
enzyme. When wild-type and mutant methionine adenosyltrans-
ferase were incubated with S-nitrosoglutathione the activity of
the wild-type remained unchanged whereas the activity of the
mutant enzyme decreased markedly. The mutant enzyme was
found to be S-nitrosylated upon incubation with the nitric oxide
donor. Treatment of the S-nitrosylated mutant enzyme with
glutathione removed most of the S-nitrosothiol groups and
restored the activity to control values. In conclusion, our results
suggest that functional S-nitrosylation sites can develop from
existing structures without drastic or large-scale amino acid
replacements.
z 1999 Federation of European Biochemical Societies.
Key words: Methionine adenosyltransferase; S-Nitrosylation
1. Introduction
Three methionine adenosyltransferases (MATs) which di¡er
with respect to tissue distribution and kinetic properties reg-
ulate the synthesis of S-adenosylmethionine (AdoMet) from
methionine and ATP in mammals [1^3]. Two of these iso-
forms (MAT I and MAT III) are a homotetramer (MAT I)
and a homodimer (MAT III) of the same K subunit (43.7
kDa) and are expressed exclusively in the adult rat liver
[1^3]. A third isoform (MAT II) is present in fetal hepato-
cytes, extrahepatic tissues, liver cancer cells and, in small
quantities, in adult liver [1^3]. MAT II is thought to consist
of two K and two L subunits [1^3]. The hepatic and extra-
hepatic K subunits are very similar and display sequence iden-
tities of about 85% [4]. The L subunit is unrelated to the K
subunit with respect to peptide maps and immunoreactivity
and has been proposed to have a regulatory function [5].
S-Nitrosylation of liver MAT isoforms (MAT I and MAT
III) is thought to be an important factor in the regulation of
hepatic AdoMet synthesis [6^9]. Nitric oxide (NO) groups
from small-mass NO donors are introduced into a speci¢c
thiol group (cysteine 121) of liver MAT inactivating the en-
zyme [7,8]. The S-nitrosylation site of liver MAT has been
recently identi¢ed and consists of two basic (arginine 357
and arginine 363) and one acidic (aspartate 355) amino acid
thought to be surrounding the target thiol (cysteine 121) [8].
This acid-base catalyzed SNO/SH exchange reaction is further
regulated by the cellular glutathione (GSH) content and the
reactivities of the NO donors [7^9]. Cysteine 121 is localized
at a ‘£exible loop’ over the active site cleft of MAT [10^12].
This loop seems to adopt two conformations, open and
closed, and in the closed conformation is thought to prevent
the entrance of the substrates to the active site [11]. Cysteine
121 is not essential for activity, since substitution of this ami-
no acid by serine has no e¡ect on hepatic MAT activity [13].
Cysteine 121 is present in all cloned and sequenced liver-spe-
ci¢c enzymes (human, rat and mouse liver), but is absent in all
other cloned and sequenced MATs including Mycoplasma
genitalium, Escherichia coli, Saccharomyces cerevisiae, Arabi-
dopsis thaliana, and mammalian MAT II, where in the corre-
sponding position there is a glycine residue [10,13,14]. The
‘£exible loop’ is exceptionally well conserved and except for
this di¡erence in position 121 and a conservative change in
position 131 (valine for isoleucine) the rest of the sequence
(around 20 amino acids) is identical in both MAT I/III and
MAT II K subunits [10,13,14]. Consequently, it would be in-
teresting to determine whether a functional S-nitrosylation
site in the MAT II K subunit could be constructed simply
by replacement of glycine 120 (which corresponds to cysteine
121 in liver MAT) by cysteine (G120C). Expression of the
human MAT II K subunit in E. coli has been shown to yield
a catalytically active enzyme [15]. Here we report that the
mutation G120C does not a¡ect the Km or Vmax of MAT II
but instead yields an enzyme that upon incubation with S-
nitrosoglutathione (GSNO) is S-nitrosylated and inactivated.
These results suggest that functional S-nitrosylation sites can
develop from existing conformations without drastic or large-
scale amino acid replacements.
2. Materials and methods
2.1. Site-directed mutagenesis
Human lymphocyte MAT gene containing the complete coding
region for MAT II [15] was subcloned into the pCAL-n-EK plasmid
(Stratagene) which allows fusion of the calmodulin binding peptide
(CBP) puri¢cation tag to the N-terminus of the MAT II coding se-
quence which is removable with enterokinase. Five MAT II missense
mutations were introduced by PCR site-directed mutagenesis [8,16].
These mutations consisted of the substitution of the residues histidine
9, alanine 60, alanine 68, glycine 120 and alanine 376 by cysteine
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(H9C, A60C, A68C, G120C and A376C). All mutants were identi¢ed
by sequencing of the complete MAT II cDNA.
2.2. Puri¢cation and characterization of wild-type and MAT II mutants
Expression of the MAT II wild-type protein and the mutants was
carried out using the BL21(DE3 pLys) E. coli strain as described
previously [8,13]. A bacterial lysate was obtained by incubation in
lysis bu¡er (50 mM Tris-HCl pH 8.0, 150 mM KCl, 1 mM imidazole,
1 mM MgSO4, 2 mM CaCl2, 10 mM L-mercaptoethanol, 0.1 mM
PMSF and 0.1 mM benzamidine) with 1 mg/ml lysozyme for 30
min followed by ¢ve sonication cycles of 30 s. For the enzyme puri-
¢cation 150 ml of the cytosolic fraction obtained from 2.5 l cultures
was loaded on a chromatography column containing 15 ml of calm-
odulin a⁄nity resin (Stratagene), equilibrated in the previously de-
scribed lysis bu¡er. The resin was washed with 10 column volumes
of lysis bu¡er and the sample was eluted with 10 column volumes of
elution bu¡er (50 mM Tris-HCl pH 8.0, 150 mM KCl, 2 mM EGTA
and 10 mM L-mercaptoethanol) and 10 ml fractions were collected.
All human MAT II activity appeared in fractions 2^7, while E. coli
activity eluted in the £owthrough fraction. The CBP tag was ¢nally
cleaved using 10 units of enterokinase (Stratagene) per milligram of
CBP fusion protein. Protein purity was greater than 95% in all cases
as determined by SDS-PAGE. Protein concentration was measured
using the Bio-Rad protein assay kit based on the Bradford assay [17].
2.3. Gel ¢ltration chromatography of WT and G120C recombinant
MAT II
Gel ¢ltration chromatography was carried out on a Superdex 200
HR 10/30 column equilibrated in bu¡er (10 mM HEPES, 10 mM
MgCl2, 1 mM EDTA and 200 mM KCl pH 7.4) at a £ow rate of
0.8 ml/min. Protein elution was performed using the same bu¡er and
followed by recording the absorbance at 280 nm. The apparent mo-
lecular weights of the recombinant proteins were determined using
cytochrome c (Mr 12 400), carbonic anhydrase (Mr 29 000), bovine
serum albumin (Mr 66 000), alcohol dehydrogenase (Mr 150 000)
and L-amylase (Mr 200 000) as marker proteins.
2.4. MAT activity measurements
MAT activity was measured as described previously by Cabrero et
al. [18] using 10 WM methionine and 5 mM ATP, in the absence of
any reducing agent. The e¡ect of GSNO on MAT activity was tested
by preincubating the enzyme with the NO donor at 37‡C for 15 min
and removing the excess of GSNO by DEAE chromatography [7,8].
2.5. Determination of MAT S-nitrosylation
MAT S-nitrosylation was measured according to the procedure
described by Ruiz et al. [7]. Puri¢ed recombinant wild-type MAT II
and G120C mutant (0.4 mg/ml) were incubated in the presence of
GSNO at 37‡C for 15 min. The excess of GSNO was removed by
DEAE chromatography. S-Nitrosylated proteins were incubated with
2.2 mM HgCl2 and the amount of NO released was measured by
chemiluminescence derived from its reaction with ozone using a Sie-
vers NOA 280 nitric oxide analyzer. Standard curves were obtained
with known GSNO concentrations.
2.6. Preparation of GSNO
GSNO was prepared according to Ruiz et al. [7]. Equimolar con-
centrations of an aqueous solution of NaNO2 and freshly prepared
GSH in 250 mM HCl and 0.1 M EDTA, pH 1.5 were mixed. The
resulting solution was incubated at room temperature for 5 min and
then neutralized with NaOH. Only freshly prepared solutions of
GSNO were used.
3. Results
We observed previously that in a model structure of liver
MAT one residue of aspartic acid (Asp-355) and two residues
of arginine (Arg-357, Arg-363) are all found in the vicinity of
the sulfur group of cysteine 121 [8]. Replacement of the acidic
(Asp-355) or basic (Arg-357, Arg-363) amino acids surround-
ing cysteine 121 leads to a marked reduction in the ability of
NO to S-nitrosylate and inactivate hepatic MAT [8]. We
therefore speculated that the S-nitrosylation of protein thiol
residues is governed by the basic and acidic amino acids sur-
rounding the target thiol. In MAT II the aspartic acid (Asp-
354) and both arginines (Arg-356, Arg-362) are present but in
position 120 (the equivalent of position 121 in liver MAT)
there is a glycine instead of a cysteine. Consequently, we pre-
pared a MAT II mutant where glycine 120 was replaced by
cysteine (G120C) and determined the ability of GSNO to in-
activate and nitrosylate the wild-type and mutant enzymes.
Wild-type and G120C mutant human recombinant extrahe-
patic MAT were e⁄ciently puri¢ed from E. coli extracts. SDS-
PAGE revealed that associated proteins did not signi¢cantly
contaminate the puri¢ed proteins (Fig. 1a). FPLC gel ¢ltra-
tion was used to demonstrate that wild-type and G120C re-
combinant extrahepatic MAT form homodimers composed of
an K subunit of Mr about 46 000 (Fig. 1b). The wild-type and
mutant enzymes have a Km for methionine and ATP of
around 15 WM and 250 WM respectively and Vmax of around
24 nmol S-adenosylmethionine/min/mg protein. When wild-
type and G120C MAT II were incubated with various con-
centrations of GSNO the activity of the wild-type enzyme
remained unchanged but the activity of the mutant enzyme
decreased up to 70% (Fig. 2). GSNO-induced G120C MAT
inactivation was due to an increase in the Km of the enzyme
for methionine and ATP without signi¢cantly changing the
Vmax. Thus, the Km of the enzyme for methionine increased
from 15.6 þ 4.1 WM in the absence of GSNO to 38.7 þ 10.7
WM in the presence of 100 WM GSNO. Similarly, the Km for
Fig. 1. Characterization of wild-type and G120C mutant MAT II.
a: MAT II puri¢ed from E. coli transformed with wild-type (WT)
or mutant (G120C) cDNA was analyzed by SDS-PAGE as de-
scribed in Section 2. Molecular size markers are indicated on the
left. b: MAT II puri¢ed from E. coli transformed with wild-type
(solid line) or mutant (dashed line) cDNA was analyzed by FPLC
gel ¢ltration as described in Section 2. FPLC gel ¢ltration was used
to demonstrate that wild-type (WT) and mutant (G120C) recombi-
nant MAT II are dimeric enzymes. Molecular size markers are indi-
cated at the top.
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ATP was 264 þ 22 WM and 408 þ 27 WM in the absence or
presence of 100 WM GSNO respectively.
S-Nitrosylation of puri¢ed wild-type and G120C MAT II
proteins was determined by photolysis chemiluminescence
[7,8]. Upon incubation with 50 WM GSNO the content of
SNO measured in G120C MAT II (1.23 þ 0.25 mol SNO/
mol subunit) was much higher than the content of SNO of
the wild-type (0.15 þ 0.12 mol SNO/mol subunit). Fig. 3 shows
that in G120C there is a close inverse correlation between the
extent of S-nitrosylation and loss of activity induced by
GSNO (r = 0.98, P6 0.001). Incorporation of 1.2 mol of
SNO/mol of MAT II subunit led to about 70% inactivation
of mutant MAT II. Maximal S-nitrosylation and inactivation
were obtained within 10 min of incubation with GSNO (data
not shown). We have previously shown that the e¡ect of
GSNO on hepatic MAT inactivation was reversible upon in-
cubation with GSH [7]. Consistently, incubation of G120C
MAT II pretreated with 50 WM GSNO (to reach an inactiva-
tion of about 70% and an incorporation of 1.23 þ 0.25 mol
SNO/mol subunit) with 5 mM GSH reduced the NO content
to 0.2 þ 0.12 mol SNO/mol subunit and returned the enzyme
activity to control values.
Liver MAT contains 10 cysteine residues per subunit [4].
Five of these cysteine residues are conserved in the extrahe-
patic enzyme whereas the other ¢ve cysteines are replaced by:
histidine 9, alanine 60, alanine 68, glycine 120 and alanine 376
[13,15]. We have replaced histidine 9 (H9C) and alanine 376
(A376C) by cysteine and observed that the addition of 100
WM GSNO had no e¡ect on the activity of these mutant
enzymes. The replacement of alanine 60 or alanine 68 by
cysteine did not yield active enzymes. These controls provide
evidence that the e¡ects on MAT II S-nitrosylation and ac-
tivity of changing glycine 120 to cysteine are speci¢c.
4. Discussion
NO modi¢es the properties and functions of numerous pro-
teins including ion channels, transcription factors, ras, a vari-
ety of enzymes and hemoglobin [19,20]. Recent evidence in-
dicates that these alterations are achieved by S-nitrosylation
of speci¢c cysteine residues or by introduction of NO groups
into transition metals present in the target proteins [19,20].
Studies with a variety of proteins [20] have suggested that
protein S-nitrosylation is an acid-base catalyzed SNO/SH ex-
change reaction where the target cysteine residue is localized
close to basic and acidic amino acids. We have recently shown
that the S-nitrosylation site of liver MAT consists of two
basic and one acidic amino acid which are thought to be
surrounding the target cysteine [8]. Little is known, however,
about how a S-nitrosylation site can evolve from existing
structures. In MAT II the acidic (Asp-354) and basic (Arg-
356, Arg-362) amino acids are conserved. We show here that
replacement of a single amino acid (Gly-120) by cysteine can
result in a functional NO binding site without a¡ecting the
kinetic parameters of the enzyme. Whereas wild-type MAT II
activity was insensitive to GSNO, in the mutant enzyme the
incorporation of about 1 mol SNO/mol of subunit led to a
marked inactivation of the enzyme which could be reversed by
incubation with millimolar GSH. In G120C MAT II, S-nitro-
sylation increased the Km for methionine and ATP of the
enzyme. This unprecedented observation suggests that simple
changes in protein sequence may provide one mechanism for
the evolution of S-nitrosylation sites.
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